Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.77 |
| ▸ | F2 | P00734 | 4/20 | 0.77 |
| ▸ | F9 | P00740 | 1/20 | 0.77 |
| ▸ | PLAU | P00749 | 1/20 | 0.77 |
| ▸ | PROC | P04070 | 1/20 | 0.77 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.77 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5377884 | 0.97 | F10 (0.73) | F10F2F9PLAUPROC | |
| SCHEMBL5383206 | 0.87 | F10 (0.59) | F10F2F9PLAUPROC | |
| SCHEMBL6162242 | 0.86 | F10 (0.78) | F10F2F9PLAUPROC | |
| Trifluoroacetic Acid SCHEMBL5384473 | 0.83 | F10 (0.74) | F10F2F9PLAUPROC | |
| SCHEMBL3833378 | 0.81 | F10 (0.80) | F10F2F9PROCPRSS1 | |
| Trifluoroacetic Acid SCHEMBL3833242 | 0.79 | F10 (0.75) | F10F2F9PROCPRSS1 | |
| SCHEMBL6603259 | 0.78 | F10 (0.64) | F10F2F9PLAUPROC | |
| SCHEMBL6603523 | 0.78 | F10 (1.00) | F10F2F9PLAUPROC | |
| SCHEMBL6605183 | 0.78 | F10 (0.65) | F10F2F9PLAUPROC | |
| SCHEMBL6605378 | 0.77 | F10 (0.66) | F10F2F9PLAUPROC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991638-B1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | claimed |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | claimed |
| US-6339099-B1 | FOR THERAPY AND PROPHYLAXIS OF THROMBOEMBOLIC DISORDER | DUPONT PHARMACEUTICALS COMPANY | 2002-01-15 | — | — | US | claimed |
| EP-0991638-B1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6906070-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
| US-6339099-B1 | FOR THERAPY AND PROPHYLAXIS OF THROMBOEMBOLIC DISORDER | DUPONT PHARMACEUTICALS COMPANY | 2002-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | F11, SERPINC1, TFPI | F10 11/4885F2 18/4885F9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.